This article needs additional citations for verification. Please help improve this articlebyadding citations to reliable sources. Unsourced material may be challenged and removed.
Find sources: "Corixa" company – news · newspapers · books · scholar · JSTOR (July 2020) (Learn how and when to remove this message) |
This article relies largely or entirely on a single source. Relevant discussion may be found on the talk page. Please help improve this articlebyintroducing citations to additional sources.
Find sources: "Corixa" company – news · newspapers · books · scholar · JSTOR (July 2022) |
Corixa was a biotechnology/pharmaceutical company based in Seattle, Washington, involved in the development of immunotherapeutics to combat autoimmune diseases, infectious diseases, and cancer. It was founded in 1994. It operated a laboratory and production facility in Hamilton, Montana.
 | |
| Company type | biotechnology/pharmaceutical |
|---|---|
| Founded | 1994 in Seattle, Washington |
| Defunct | March 31, 2006 (2006-03-31) |
| Successor | acquired by GlaxoSmithKline |
| Headquarters |
Seattle
,
Washington
|
Number of locations | 2 |
| Parent | GlaxoSmithKline (United States)  |
In 2005, the European pharmaceuticals giant GlaxoSmithKline completed the acquisition of Corixa.[1] GSK had formerly made use of the Corixa's MPL (Monophosphoryl lipid A, a derivative of the lipid A molecule), an adjuvant in some of their vaccines.
47°36′58″N 122°20′03″W / 47.615976°N 122.334242°W / 47.615976; -122.334242
 | This article about a medical, pharmaceuticalorbiotechnological corporation or company is a stub. You can help Wikipedia by expanding it. |